Several pharmacological interventions have evidence supporting benefit in canine cognitive dysfunction syndrome, offering welfare improvement beyond environmental management alone.
Drug therapy for CDS provides welfare benefit beyond what environmental modification and dietary change alone can achieve. Selegiline has the strongest evidence base and represents an accessible treatment option for dogs in early to moderate disease stages. The welfare improvements in responding dogs are meaningful: reduced nighttime vocalization improves sleep for both dog and owner, reduced disorientation reduces anxiety, and maintained learned behaviors preserves quality of life. Starting treatment earlier in disease progression may slow decline. The welfare imperative is not to attribute CDS signs to normal aging and withhold potentially beneficial treatment.